Cresset Asset Management LLC reduced its stake in DaVita Inc. (NYSE:DVA - Free Report) by 73.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,517 shares of the company's stock after selling 9,752 shares during the period. Cresset Asset Management LLC's holdings in DaVita were worth $526,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently made changes to their positions in the stock. Crestline Management LP boosted its stake in shares of DaVita by 19.1% in the 4th quarter. Crestline Management LP now owns 5,034 shares of the company's stock valued at $753,000 after purchasing an additional 808 shares in the last quarter. BOKF NA boosted its stake in shares of DaVita by 55.2% in the 4th quarter. BOKF NA now owns 8,963 shares of the company's stock valued at $1,375,000 after purchasing an additional 3,188 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of DaVita in the 4th quarter valued at approximately $322,000. Ameriprise Financial Inc. boosted its stake in shares of DaVita by 27.2% in the 4th quarter. Ameriprise Financial Inc. now owns 32,545 shares of the company's stock valued at $4,867,000 after purchasing an additional 6,951 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV raised its holdings in DaVita by 21.7% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 12,404 shares of the company's stock valued at $1,855,000 after buying an additional 2,212 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the stock. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a report on Friday, February 21st. Finally, StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, DaVita presently has an average rating of "Hold" and an average target price of $166.33.
Get Our Latest Stock Analysis on DaVita
DaVita Trading Up 1.1%
DaVita stock traded up $1.63 during mid-day trading on Friday, hitting $145.23. 738,898 shares of the stock were exchanged, compared to its average volume of 830,380. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12 month low of $131.44 and a 12 month high of $179.60. The firm's fifty day simple moving average is $145.68 and its two-hundred day simple moving average is $153.48. The stock has a market capitalization of $11.16 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 1.07 and a beta of 1.14.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.25. The firm had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The company's revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.26 EPS. Analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
